CliffBio
small molecule

CINVANTI

APREPITANT

Loss of exclusivitySeptember 2035latest FDA-listed patent expiry
CompanyHeron Therapeutics →View the full company profile on CliffBio

Drug detail

Brand nameCINVANTI
Active ingredientAPREPITANT
Strength130MG/18ML (7.2MG/ML)
Dosage formEMULSION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalNovember 2017
Marketing statusRX

Listed patents

PatentExpiresType
9808465September 2035use U-2161
10953018September 2035use U-2161
9974794September 2035product
9561229September 2035product
10624850September 2035use U-2161
12115254September 2035product
9974793September 2035product
9974742September 2035product
12115255September 2035product
11173118September 2035product
12290520September 2035product
10500208September 2035product
11744800September 2035product

More from Heron Therapeutics

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

CINVANTI patent cliff — loss of exclusivity September 2035 | CliffBio